CVS will expand its pilot mental health program; CMS adopts new rules to lower out-of-pocket costs; a study highlights overuse of cervical cancer screening tests.
CVS is leading the way in trying to fill gaps in access to mental health services, NPR reported. To do so, the pharmacy chain has piloted a counseling service in some of its retail stores and negotiates with insurance companies to cover visits in an effort to reduce costs. The COVID-19 pandemic has led to overbooked therapists while many do not accept insurance, forcing customers to pay out-of-pocket for each visit. The CVS pilot program launched in January and currently operates in 12 stores across Houston, Texas; Philadelphia, Pennsylvania; and Tampa, Florida. This year, it plans to expand to 34 stores and target communities where mental health care isn’t readily available.
CMS today announced it has adopted new provisions to lower maximum out-of-pocket costs to consumers by $400. The center will do so while also increasing competition and improving consumer experiences for Americans who will rely on the Federal Health Insurance Marketplaces in plan year 2022. The second 2022 payment notice also includes provisions to help consumers better distinguish between plan options and increase opportunities to qualify for future special enrollment periods (SEP). Thus far, an additional 800,000 individuals enrolled in the Affordable Care Act under the SEP enacted by the Biden administration.
A new study published in JAMA Network Open found that among women with average risk of cervical cancer in the United States, overuse of screening tests is common. The cohort study, which included nearly 2,300,000 commercially insured women, revealed around 65% underwent repeat testing within 36 months of index testing. Researchers noted interventions to mitigate overuse of this testing are of interest as they can help reduce patient harm and medical waste. Further evaluations of interventions aligning clinical practice with evidence-based guidelines are warranted, they concluded.
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
What We’re Reading: HHS' Funding Flat; Mifepristone Safety; Insulin Shortage
March 25th 2024Flat funding for Health and Human Services (HHS) leaves critical health initiatives stagnant; Supreme Court weighs tightening regulations on abortion pill; manufacturing delay sparks access concerns for insulin medication.
Read More